Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma

被引:9
|
作者
Yamashita, Suguru [1 ]
Overman, Michael J. [2 ]
Wang, Huamin [3 ]
Zhao, Jun [3 ]
Okuno, Masayuki [1 ]
Goumard, Claire [1 ]
Tzeng, Ching-Wei [1 ]
Kim, Michael [1 ]
Fleming, Jason B. [1 ]
Vauthey, Jean-Nicolas [1 ]
Katz, Matthew H. [1 ]
Lee, Jeffrey E. [1 ]
Conrad, Claudius [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
PANCREATIC DUCTAL ADENOCARCINOMA; COLORECTAL LIVER METASTASES; PHASE-II; FRACTIONATED CHEMORADIATION; NEOADJUVANT CHEMORADIATION; TRACT CANCER; VATER; CHEMOTHERAPY; GEMCITABINE; CARCINOMA;
D O I
10.1245/s10434-017-6098-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established. Methods. A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (>= 50% of viable residual tumor cells). Uni- and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS). Results. For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS. Conclusion. The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.
引用
收藏
页码:3954 / 3963
页数:10
相关论文
共 50 条
  • [41] Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy
    Stark, Alexander P.
    Ikoma, Naruhiko
    Chiang, Yi-Ju
    Estrella, Jeannelyn S.
    Das, Prajnan
    Minsky, Bruce D.
    Blum, Mariela M.
    Ajani, Jaffer A.
    Mansfield, Paul
    Badgwell, Brian D.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (11) : 3602 - 3610
  • [42] Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer
    Perri, Giampaolo
    Prakash, Laura
    Wang, Huamin
    Bhosale, Priya
    Varadhachary, Gauri R.
    Wolff, Robert
    Fogelman, David
    Overman, Michael
    Pant, Shubham
    Javle, Milind
    Koay, Eugene
    Herman, Joseph
    Kim, Michael
    Ikoma, Naruhiko
    Tzeng, Ching-Wei
    Lee, Jeffrey E.
    Katz, Matthew H. G.
    ANNALS OF SURGERY, 2021, 273 (04) : 806 - 813
  • [43] Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means?
    John C. Mansour
    Roderich E. Schwarz
    Annals of Surgical Oncology, 2009, 16 : 1465 - 1479
  • [44] Pathologic response to preoperative systemic therapy: The new biological paradigm for predicting outcome and planning therapy
    Anderson, BO
    ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (07) : 713 - 715
  • [45] Pathologic Response to Preoperative Systemic Therapy: The New Biological Paradigm for Predicting Outcome and Planning Therapy
    Benjamin O. Anderson
    Annals of Surgical Oncology, 2003, 10 : 713 - 715
  • [46] Novel Single-Nucleotide Polymorphism Markers Predictive of Pathologic Response to Preoperative Chemoradiation Therapy in Rectal Cancer Patients
    Kim, Jin C.
    Ha, Ye J.
    Roh, Seon A.
    Cho, Dong H.
    Choi, Eun Y.
    Kim, Tae W.
    Kim, Jong H.
    Kang, Tae W.
    Kim, Seon Y.
    kim, Yong S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (02): : 350 - 357
  • [47] Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma
    Abe, Tomoyuki
    Amano, Hironobu
    Kobayashi, Tsuyoshi
    Hanada, Keiji
    Nakahara, Masahiro
    Ohdan, Hideki
    Noriyuki, Toshio
    EJSO, 2018, 44 (10): : 1573 - 1579
  • [48] Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response
    Barrak, Dany
    Villano, Anthony M.
    Villafane-Ferriol, Nicole
    Stockton, Leah G.
    Hill, Maureen, V
    Deng, Mengying
    Handorf, Elizabeth A.
    Reddy, Sanjay S.
    EJSO, 2022, 48 (06): : 1356 - 1361
  • [49] Total Neoadjuvant Therapy Offers Improved Survival and Pathologic Response in Pancreatic Adenocarcinoma
    O'Halloran, E. A.
    Lefton, M.
    Rhodes, L.
    Hoffman, J.
    Cukierman, E.
    Reddy, S.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S22 - S22
  • [50] Pathologic Evaluation of Endoscopically Resected Non-Ampullary Duodenal Lesions: A Single Center Experience
    Taskin, Orhun Cig
    Aslan, Fatih
    Mericoz, Cisel Aydin
    Adsay, Volkan
    Kapran, Yersu
    TURKISH JOURNAL OF PATHOLOGY, 2020, 36 (02) : 109 - 115